SPOTLIGHT: Novartis touts cancer data

Email LinkedIn
Tools


Novartis has released positive data for RAD001 in advance of ASCO. According to interim data the therapy extended time without tumor growth from 1.9 months to 4 months and reduced the risk of progression by 70 percent. Release | Report

Filed Under